Background illustration for clinical trials search

Chronic Lymphocytic Leukemia Clinical Trials

Browse 1,522 chronic lymphocytic leukemia clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

for
Metastatic Malignant Solid Neoplasm
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06606990

Phase 1, Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

for
Advanced Solid Tumor
Location: Fairfax VA, Cleveland OH, Dallas TX, San Antonio TX,
Sponsor: 1ST Biotherapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05761223

Phase 1, Phase 2, Recruiting

UNC Childhood, Adolescent, and Young Adult Cancer Cohort

for
Pediatric Cancer, Cancer, Cancer Metastatic, Survivorship
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 1 - 39

Code: NCT05096923

Recruiting

Exercise and Relaxation Intervention for Young Adult Cancer Survivors

for
Cancer
Location: Providence RI
Sponsor: The Miriam Hospital

Sex: All

Age: 18 - 39

Code: NCT00801008

Recruiting

The Effects of Case Management in a Medicaid Managed Care Plan

for
Neoplasms, Heart Diseases, Adrenal Cortex Diseases
Location: Brooklyn NY
Sponsor: Metropolitan Jewish Health System

Sex: All

Age: 18+

Code: NCT00385879

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of MGC028 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma,
Location: Boston MA, New York NY, Grand Rapids MI, San Antonio TX,
Sponsor: MacroGenics

Sex: All

Age: 18+

Code: NCT06723236

Phase 1, Recruiting

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

for
Malignant Neoplasm
Location: Jersey City NJ, New Brunswick NJ
Sponsor: Rutgers, The State University of New Jersey

Sex: All

Age: 1+

Code: NCT02688517

Recruiting

Study of ACR-2316 in Specific Advanced Solid Tumors

for
Specific Advanced Solid Tumors
Location: Boston MA, Providence RI, The Bronx NY, Fairfax VA,
Sponsor: Acrivon Therapeutics

Sex: All

Age: 18+

Code: NCT06667141

Phase 1, Phase 2, Recruiting

A Phase I Open-label Study for Subjects With Advanced Malignancies

for
Advanced Solid Malignancies
Location: Jacksonville FL, Rochester MN, Phoenix AZ
Sponsor: Athenex, Inc.

Sex: All

Age: 18+

Code: NCT04136834

Phase 1, Recruiting

Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)

for
Cancer
Location: New York NY
Sponsor: National Center for Research Resources (NCRR)

Sex: All

Age: 18+

Code: NCT00006199

Phase 1, Recruiting

Studying TAK-243 in Patients With Advanced Cancer

for
Advanced Lymphoma, Advanced Malignant Solid Neoplasm,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06223542

Phase 1, Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

for
Locally Advanced Malignant Solid Neoplasm,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 16+

Code: NCT04879121

Phase 2, Recruiting

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

for
Lymphatic Diseases, Hematopoietic Malignancy
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 0+

Code: NCT01451502

Recruiting

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Boston MA, St Louis MO
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07137416

Phase 1, Recruiting

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

for
Malignant Solid Neoplasm
Location: Marshalltown IA, Ames IA, Boone IA, Fort Dodge IA,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04871542

Recruiting

PEN-866 in Patients With Advanced Solid Malignancies

for
Carcinoma, Endometrial Adenocarcinoma, Neoplasms,
Location: Philadelphia PA, Bethesda MD, Fairfax VA,
Sponsor: Tarveda Therapeutics

Sex: All

Age: 18+

Code: NCT03221400

Phase 1, Phase 2, Recruiting

Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated With Radiation

for
Cancer
Location: Dallas TX
Sponsor: University of Texas Southwestern Medical Center

Sex: All

Age: 18 - 70+

Code: NCT03617237

Recruiting
New

Keep Social Randomized Controlled Trial for Young Adults With Cancer

for
Cancer
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 22 - 39

Code: NCT07788339

Recruiting
New

Feasibility Pilot of AYA-PARTNER

for
Cancer, Malignancies Multiple
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18 - 39

Code: NCT07829146

Recruiting
New

Human Blood Cell Disorders Tissue Bank

for
Human Blood Cell Disorders,
Location: Manhasset NY
Sponsor: Northwell Health

Sex: All

Age: 18 - 70+

Code: NCT00902447

Recruiting

What is chronic lymphocytic leukemia?

Chronic lymphocytic leukemia, or CLL, is a slow growing cancer of B lymphocytes that build up in the blood, bone marrow, and lymph nodes. Most people are diagnosed around age 70, often with no symptoms; when symptoms come, they include tiredness, swollen lymph nodes, frequent infections, night sweats, and weight loss. Small lymphocytic lymphoma is the same disease when the cells sit mainly in lymph nodes, so it is studied in the same trials.

When treatment is needed, it is now mostly targeted pills: BTK inhibitors taken continuously, or venetoclax based combinations taken for a fixed time. CAR T cell therapy was approved for CLL in 2024 for people whose disease has stopped responding to both. Genetic features such as TP53 mutation, deletion 17p, and IGHV status strongly predict how CLL behaves and which trials fit. Other leukemias are on our leukemia clinical trials page.

Types of CLL clinical trials

Who can participate in CLL clinical trials?

How CLL is staged, and why it matters for trials

How to enroll in a CLL clinical trial